Parabilis Medicines IPO Performance
Parabilis Medicines Inc (NASDAQ: PBLS) opened trading at $33.35 per share, representing a 67% premium to its $20.00 IPO price. The share price later moderated to $29.50, still reflecting a 47.5% uplift from the IPO price.
The company priced an upsized initial public offering on Tuesday, issuing 33,500,000 shares of common stock at $20.00 each. Underwriters received a 30‑day option to purchase an additional 5,025,000 shares at the IPO price, subject to customary discounts and commissions. The offering is slated to close on or about June 11, 2026, pending standard closing conditions.
Parabilis expects gross proceeds of $670 million from the IPO before deducting underwriting discounts, commissions, and other offering expenses. In a concurrent private placement, the company agreed to sell 4,166,666 shares to Regeneron Pharmaceuticals Inc at $18.00 per share, anticipated to generate approximately $75 million in proceeds.
Active book‑running managers for the offering are Leerink Partners, BofA Securities, Evercore ISI, and Guggenheim Securities, with LifeSci Capital LLC serving as the passive book‑running manager. Parabilis is a clinical‑stage biopharmaceutical firm developing medicines that target historically undruggable proteins using its proprietary Helicons platform, which engineers stabilized helical peptides to bind and modulate such proteins.